EligibleTrials

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

Recruiting · NCT07592689 · Interventional (participants receive a specific treatment) · Lead sponsor: Definium Therapeutics US, Inc.

View the official record on ClinicalTrials.gov →
Depression

Interventions studied

DT120Placebo

What this trial is about

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

Who can take part

Age range
18 Years to 74 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

30 locations listed across 17 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.